ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Purchased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC boosted its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 22,300.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,600 shares of the company’s stock after buying an additional 5,575 shares during the quarter. Nisa Investment Advisors LLC’s holdings in ARS Pharmaceuticals were worth $31,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SPRY. China Universal Asset Management Co. Ltd. raised its holdings in ARS Pharmaceuticals by 352.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company’s stock worth $61,000 after purchasing an additional 8,652 shares during the period. Letko Brosseau & Associates Inc. acquired a new position in shares of ARS Pharmaceuticals during the 3rd quarter worth approximately $136,000. Barclays PLC purchased a new position in shares of ARS Pharmaceuticals during the 2nd quarter valued at approximately $138,000. FAS Wealth Partners Inc. grew its stake in ARS Pharmaceuticals by 34.2% in the 3rd quarter. FAS Wealth Partners Inc. now owns 45,970 shares of the company’s stock valued at $174,000 after acquiring an additional 11,720 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in ARS Pharmaceuticals by 9.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 83,924 shares of the company’s stock valued at $317,000 after acquiring an additional 7,024 shares during the period. Hedge funds and other institutional investors own 68.16% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SPRY. SVB Leerink upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $6.00 to $18.00 in a research report on Tuesday, March 5th. Wedbush reiterated an “outperform” rating and issued a $19.00 price objective on shares of ARS Pharmaceuticals in a report on Monday, March 11th. William Blair raised ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 20th. Finally, Leerink Partnrs raised ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 5th.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, insider Sarina Tanimoto sold 98,778 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $9.02, for a total value of $890,977.56. Following the completion of the sale, the insider now directly owns 1,747,294 shares of the company’s stock, valued at approximately $15,760,591.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Sarina Tanimoto sold 98,778 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $9.02, for a total value of $890,977.56. Following the completion of the sale, the insider now owns 1,747,294 shares of the company’s stock, valued at $15,760,591.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ra Capital Management, L.P. bought 437,600 shares of ARS Pharmaceuticals stock in a transaction on Monday, March 25th. The shares were purchased at an average cost of $9.06 per share, for a total transaction of $3,964,656.00. Following the completion of the purchase, the director now directly owns 8,994,374 shares of the company’s stock, valued at $81,489,028.44. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 503,260 shares of company stock valued at $4,612,480. Insiders own 35.60% of the company’s stock.

ARS Pharmaceuticals Trading Down 3.1 %

SPRY opened at $8.21 on Tuesday. ARS Pharmaceuticals, Inc. has a twelve month low of $2.55 and a twelve month high of $11.27. The firm has a market capitalization of $792.27 million, a PE ratio of -14.40 and a beta of 0.83. The firm’s 50-day moving average price is $8.77 and its 200 day moving average price is $6.34.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its earnings results on Thursday, March 21st. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.07. As a group, analysts predict that ARS Pharmaceuticals, Inc. will post -0.69 earnings per share for the current fiscal year.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.